Phase 3 ECHO: Safety Data Review

Results from the phase 3 TRIANGLE trial showed prolonged failure-free survival and overall survival with ibrutinib and CIT vs CIT plus ASCT alone.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.